Breast cancer is one of the most common cancer and leading causes of death in women in the United States and Worldwide.About 90%of breast cancers belong to ER+or HER2+subtypes and are driven by key breast cancer genes...Breast cancer is one of the most common cancer and leading causes of death in women in the United States and Worldwide.About 90%of breast cancers belong to ER+or HER2+subtypes and are driven by key breast cancer genes Estrogen Receptor and HER2,respectively.Despite the advances in anti-estrogen(endocrine)and anti-HER2 therapies for the treatment of these breast cancer subtypes,unwanted side effects,frequent recurrence and resistance to these treatments remain major clinical challenges.Recent studies have identified ER coactivator MED1 as a key mediator of ER functions and anti-estrogen treatment resistance.Interestingly,MED1 is also coamplified with HER2 and activated by the HER2 signaling cascade,and plays critical roles in HER2-mediated tumorigenesis and response to anti-HER2 treatment as well.Thus,MED1 represents a novel crosstalk point of the HER2 and ER pathways and a highly promising new therapeutic target for ER+and HER2+breast cancer treatment.In this review,we will discuss the recent progress on the role of this key ER/HER2 downstream effector MED1 in breast cancer therapy resistance and our development of an innovative RNA nanotechnology-based approach to target MED1 for potential future breast cancer therapy to overcome treatment resistance.展开更多
基金This work was supported by National Cancer Institute(NCI)R01 grants(CA197865,CA229869)University of Cincinnati Cancer Center and Ride Cincinnati Award(to X.Zhang).
文摘Breast cancer is one of the most common cancer and leading causes of death in women in the United States and Worldwide.About 90%of breast cancers belong to ER+or HER2+subtypes and are driven by key breast cancer genes Estrogen Receptor and HER2,respectively.Despite the advances in anti-estrogen(endocrine)and anti-HER2 therapies for the treatment of these breast cancer subtypes,unwanted side effects,frequent recurrence and resistance to these treatments remain major clinical challenges.Recent studies have identified ER coactivator MED1 as a key mediator of ER functions and anti-estrogen treatment resistance.Interestingly,MED1 is also coamplified with HER2 and activated by the HER2 signaling cascade,and plays critical roles in HER2-mediated tumorigenesis and response to anti-HER2 treatment as well.Thus,MED1 represents a novel crosstalk point of the HER2 and ER pathways and a highly promising new therapeutic target for ER+and HER2+breast cancer treatment.In this review,we will discuss the recent progress on the role of this key ER/HER2 downstream effector MED1 in breast cancer therapy resistance and our development of an innovative RNA nanotechnology-based approach to target MED1 for potential future breast cancer therapy to overcome treatment resistance.
